## Heng Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5286505/publications.pdf

Version: 2024-02-01

1163117 888059 29 352 8 17 citations h-index g-index papers 29 29 29 566 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 1044-1052.e15.	0.8	9
2	Effect of early hypoglycaemia on hospitalization outcomes in patients undergoing coronary artery bypass grafting. Diabetes Research and Clinical Practice, 2022, 186, 109830.	2.8	3
3	Sinoatrial nodal artery injury in thoracoscopic epicardial ablation for atrial fibrillation. European Journal of Cardio-thoracic Surgery, 2021, 59, 409-416.	1.4	О
4	Glycemic control and risk factors for inâ€hospital mortality and vascular complications after coronary artery bypass grafting in patients with and without preexisting diabetes. Journal of Diabetes, 2021, 13, 232-242.	1.8	8
5	Trends of Coronary Artery Bypass Grafting Performance in a Cohort of Hospitals in China Between 2013 and 2018. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007025.	2.2	8
6	Midterm results of stand-alone thoracoscopic epicardial ablation with box lesion for atrial fibrillation. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 354-361.	1.1	3
7	Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery: The MISSION-1 randomized controlled trial. American Heart Journal, 2021, 237, 79-89.	2.7	3
8	Assessing the association of appropriateness of coronary revascularization and 1-year clinical outcomes for patients with stable coronary artery disease in China. Chinese Medical Journal, 2020, 133, 1-8.	2.3	9
9	Elevated postoperative serum uric acid is associated with major adverse events following coronary artery bypass grafting. Journal of Cardiac Surgery, 2020, 35, 2559-2566.	0.7	4
10	Long-Term Graft Patency After Off-Pump and On-Pump Coronary Artery Bypass: AÂCORONARY Trial Cohort. Annals of Thoracic Surgery, 2020, 110, 2055-2061.	1.3	5
11	Mis-estimation of coronary lesions and rectification by SYNTAX score feedback for coronary revascularization appropriateness. Chinese Medical Journal, 2020, 133, 1276-1284.	2.3	1
12	Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization. American Heart Journal, 2020, 228, 17-26.	2.7	30
13	A giant right coronary artery aneurysm caused by congenital coronary fistula. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.6	2
14	Revascularization for Coronary Artery Disease: Principle and Challenges. Advances in Experimental Medicine and Biology, 2020, 1177, 75-100.	1.6	10
15	Quality Measurement and Improvement Study of Surgical Coronary Revascularization. Chinese Medical Journal, 2018, 131, 1480-1489.	2.3	2
16	Comparing Outcomes of Coronary Artery Bypass Grafting Among Large Teaching and Urban Hospitals in China and the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	26
17	Updated evidence for left main coronary artery disease: Practice versus the consensus. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 312-313.	0.8	3
18	The China Patient-Centred Evaluative Assessment of Cardiac Events (China PEACE)-Prospective Study of 3-Vessel Disease: rationale and design. BMJ Open, 2016, 6, e009743.	1.9	1

#	Article	IF	CITATIONS
19	Common Variant in Glycoprotein la Increases Longâ€Term Adverse Events Risk After Coronary Artery Bypass Graft Surgery. Journal of the American Heart Association, 2016, 5, .	3.7	7
20	Coronary Artery Bypass Graft Surgery andÂPercutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2016, 9, 1102-1111.	2.9	42
21	Response to Letters Regarding Article, "Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery― Circulation, 2016, 133, e394-5.	1.6	O
22	Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study. American Heart Journal, 2016, 178, 9-18.	2.7	5
23	The Chinese Cardiac Surgery Registry: Design and Data Audit. Annals of Thoracic Surgery, 2016, 101, 1514-1520.	1.3	42
24	Efficacy of Long-Term $\hat{l}^2$ -Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation, 2015, 131, 2194-2201.	1.6	64
25	Use of Pulmonary Artery Catheter in Coronary Artery Bypass Graft. Costs and Long-Term Outcomes. PLoS ONE, 2015, 10, e0117610.	2.5	16
26	Influence of Diabetes Mellitus on Long-Term Clinical and Economic Outcomes After Coronary Artery Bypass Grafting. Annals of Thoracic Surgery, 2014, 97, 2073-2079.	1.3	34
27	Giant Intravenous Leiomyomatosis With Intracardiac Extension. Annals of Thoracic Surgery, 2012, 94, 1013.	1.3	4
28	Retinoblastoma 94 Enhances Radiation Treatment of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. Journal of Radiation Research, 2012, 53, 117-124.	1.6	8
29	Complete Resection of a Mediastinal Solitary Extramedullary Plasmacytoma and Reconstruction of Right Pulmonary Artery and Superior Vena Cava. Annals of Thoracic Surgery, 2011, 92, 2244-2246.	1.3	3